Seven-day antibiotic course delivers similar outcomes to 14-days for Gram-negative bacteraemia

April 21, 2018

Madrid, Spain: A seven-day course of antibiotic treatment for Gram-negative bacteraemia (GNB), a serious infection that occurs when bacteria get into the bloodstream, was shown to offer similar patient outcomes as a 14-day course, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) [1].

Researchers assessed several primary outcomes, including mortality and whether a patient was readmitted to the hospital or had to remain in hospital longer than 14 days. In the group of 306 patients treated with a seven-day course, 46%, or 141 patients, experienced these primary outcomes. In the group of 298 patients who received the longer treatment course, that figure was 50%, or 149 patients.

The findings of a 604-patient clinical trial presented by Dr Dafna Yahav from Tel Aviv University show that mortality rate and other outcomes are similar in the shorter treatment length. Additionally, the shorter treatment may allow patients to return to their everyday activity faster.

"In patients hospitalized with GNB and sepsis resolution before day seven, a course of seven antibiotic days was not inferior to 14 days, reduced antibiotic days and resulted in a more rapid return to baseline activity," Yahav said. "This could lead to a change in accepted management algorithms and shortened antibiotic therapy. Potentially, though we did not show that in our trial, it may lead to reduced cost, resistance development and adverse events."

GNB is a major cause of morbidity and mortality in hospitalized patients. It occurs when bacteria get into the bloodstream as a result of an infection (e.g. a urinary tract infection), surgery or the inappropriate use of medical devices (e.g. catheters). There has been little data available to physicians to assist them in assigning the most beneficial length of antibiotic treatment.

Yahav anticipates that healthcare workers will implement shorter treatment protocols based on these findings. "Shorter therapy had no proven disadvantages. As true for all trials, before physicians use our findings to lead their therapy they should verify that our results are valid for their patients. We included patients that were stable at time of randomization, mostly patients with UTI (68%) and with Enterobacteriaceae as the causative organism (90%)."

Yahav and last author Mical Paul assessed the outcomes for patients admitted to three hospitals in Israel and Italy between January 2013 and August 2017. They analysed 90-day outcomes for 604 patients, 306 patients received a seven-day course of antibiotics and 298 patients received the longer 14-day treatment. Patients with ongoing sepsis or cases where there was an uncontrolled source of infection were excluded from the study.

Additionally, the researchers examined a host of other patient outcomes, such as mortality at 30 and 90 days, whether or not the patient developed secondary infections, if they developed a Clostridium difficile infection that can be common after antibiotic treatment. Yahav's team also noted total number of days patients were treated with antibiotics, remained in hospital, their functional capacity, how long it took them to return to everyday activities, any development of resistance or other negative side effects of treatment.

Thirty-six patients on the shorter treatment course, or 11.8%, had died at the 90-day mark compared with 32 patients, or 10.7%, in the longer treatment group.

In the shorter treatment group, the number of antibiotic days was reduced significantly. Those who were part of the short-term treatment arm were treated a median five days compared with those of the long-term arm, which were treated for a median 12 days. This resulted in a reduction of 1,551 antibiotic days and, Zahav said, had the benefit of allowing patients to return to regular daily activities faster. Patients in the seven-day group were able to return to baseline activities in a range of zero to just over eight weeks. The 14-day group saw a slower return to baseline activities, within a range of one to twelve weeks.
-end-
Abstract no: O1120, Seven versus 14 antibiotic days for the treatment of Gram-negative bacteraemia: non-inferiority randomized controlled trial, session Clinical Trials, 16:00 - 18:00, Sunday, 22 April 2018, Hall Q

[1] The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). This year it will take place from 21 - 24 April 2018 in Madrid, Spain. At the world's largest congress combining the fields of infectious diseases and clinical microbiology, researchers will present more than 3,000 regular and late-breaking abstracts with the latest findings and recommendations, which are set to help improve diagnosis, prevention and treatment of infection-related diseases. The congress offers almost 200 sessions, including keynote lectures, symposia, oral sessions, educational workshops and meet-the-expert session. ECCMID expects approximately 13,000 participants from more than 100 countries.

About ESCMID

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) is a non-profit organization dedicated to improving the diagnosis, treatment and prevention of infectious diseases in Europe and beyond. The society promotes and supports research, education, training and good medical practice in infection-related disciplines with a special focus on antimicrobial resistance to build capacity throughout the world. http://www.escmid.org

Contact

Chantal Britt
ESCMID Communications Manager
ESCMID Executive Office
P.O. Box 214, CH-4010 Basel
Phone +41 61 508 01 57
Mobile +41 76 588 08 24
Email chantal.britt@escmid.org
http://www.escmid.org

Tara Giroud
ECCMID Communications Assistant
Mobile +41 78 705 79 85
Email taragiroud@gmail.com

European Society of Clinical Microbiology and Infectious Diseases

Related Infectious Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Forecasting elections with a model of infectious diseases
Election forecasting is an innately challenging endeavor, with results that can be difficult to interpret and may leave many questions unanswered after close races unfold.

COVID-19 a reminder of the challenge of emerging infectious diseases
The emergence and rapid increase in cases of coronavirus disease 2019 (COVID-19), a respiratory illness caused by a novel coronavirus, pose complex challenges to the global public health, research and medical communities, write federal scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) and from the Centers for Disease Control and Prevention (CDC).

Certain antidepressants could provide treatment for multiple infectious diseases
Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.

Opioid epidemic is increasing rates of some infectious diseases
The US faces a public health crisis as the opioid epidemic fuels growing rates of certain infectious diseases, including HIV/AIDS, hepatitis, heart infections, and skin and soft tissue infections.

Infectious diseases could be diagnosed with smartphones in sub-Saharan Africa
A new Imperial-led review has outlined how health workers could use existing phones to predict and curb the spread of infectious diseases.

The Lancet Infectious Diseases: Experts warn of a surge in vector-borne diseases as humanitarian crisis in Venezuela worsens
The ongoing humanitarian crisis in Venezuela is accelerating the re-emergence of vector-borne diseases such as malaria, Chagas disease, dengue, and Zika virus, and threatens to jeopardize public health gains in the country over the past two decades, warn leading public health experts.

Glow-in-the-dark paper as a rapid test for infectious diseases
Researchers from Eindhoven University of Technology (The Netherlands) and Keio University (Japan) present a practicable and reliable way to test for infectious diseases.

Math shows how human behavior spreads infectious diseases
Mathematics can help public health workers better understand and influence human behaviors that lead to the spread of infectious disease, according to a study from the University of Waterloo.

Many Americans say infectious and emerging diseases in other countries will threaten the US
An overwhelming majority of Americans (95%) think infectious and emerging diseases facing other countries will pose a 'major' or 'minor' threat to the U.S. in the next few years, but more than half (61%) say they are confident the federal government can prevent a major infectious disease outbreak in the US, according to a new national public opinion survey commissioned by Research!America and the American Society for Microbiology.

Read More: Infectious Diseases News and Infectious Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.